KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory: 2009-2025

Historic Inventory for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $185.8 million.

  • Halozyme Therapeutics' Inventory rose 41.38% to $185.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.8 million, marking a year-over-year increase of 41.38%. This contributed to the annual value of $141.9 million for FY2024, which is 11.17% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Inventory of $185.8 million as of Q3 2025, which was up 2.36% from $181.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Inventory peaked at $185.8 million during Q3 2025, and registered a low of $47.8 million during Q1 2022.
  • Moreover, its 3-year median value for Inventory was $141.9 million (2024), whereas its average is $148.2 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Inventory fell by 18.14% in 2022, and later skyrocketed by 125.12% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Inventory (Quarterly) stood at $53.9 million in 2021, then spiked by 85.73% to $100.1 million in 2022, then grew by 27.44% to $127.6 million in 2023, then grew by 11.17% to $141.9 million in 2024, then skyrocketed by 41.38% to $185.8 million in 2025.
  • Its last three reported values are $185.8 million in Q3 2025, $181.5 million for Q2 2025, and $164.9 million during Q1 2025.